Neurotransmitters, psychotropic drugs and microglia: Clinical implications for psychiatry

Current Medicinal Chemistry

Volumn 20, Issue 3, 2013, Pages 331-344

  Kato, T A ^a,b   Yamauchi, Y ^a   Horikawa, H ^a   Monji, A ^c   Mizoguchi, Y ^c   Seki, Y ^c   Hayakawa, K ^a   Utsumi, H ^b   Kanba, S ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c SAGA UNIVERSITY   (Japan)

Author keywords

Antidepressants; Antiepileptics; Antipsychotics; BDNF; Depression; Dopamine; Epilepsy; Microglia; Minocycline; Norepinephrine; Psychiatry; Schizophrenia; Serotonin

Indexed keywords

ACETYLCHOLINE; ADENOSINE TRIPHOSPHATE; AMYLOID PRECURSOR PROTEIN; ANTIDEPRESSANT AGENT; CUPRIZONE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; DOPA; DOPAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR; FLUOXETINE; GLUTAMATE RECEPTOR; GLUTAMIC ACID; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1 RECEPTOR TYPE II; INTERLEUKIN 1BETA; INTERLEUKIN 2; IONOTROPIC RECEPTOR; MESSENGER RNA; METABOTROPIC RECEPTOR; NEUROTRANSMITTER; NICOTINIC RECEPTOR; NORADRENALIN; PSYCHOTROPIC AGENT; QUETIAPINE; RISPERIDONE; SEROTONIN; TRICYCLIC ANTIDEPRESSANT AGENT; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; AUTISM; BRAIN SLICE; CELL ACTIVATION; CENTRAL NERVOUS SYSTEM; CYTOKINE RELEASE; DEPRESSION; DOPAMINE METABOLISM; EPILEPSY; HUMAN; IN VITRO STUDY; INFLAMMATORY CELL; MAJOR DEPRESSION; MENTAL DISEASE; MICROGLIA; NERVE CELL NETWORK; NEUROPSYCHIATRY; NONHUMAN; PHAGOCYTOSIS; POSITRON EMISSION TOMOGRAPHY; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCHIZOPHRENIA; SYNAPSE;

EID: 84878001014     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986713804870800     Document Type: Article

References (228)

1. Miyamoto, S.; Duncan, G. E.; Marx, C. E.; Lieberman, J. A., Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol. Psychiatry, 2005, 10 (1), 79-104. (Pubitemid 40139590)
2. Kapur, S.; Mamo, D., Half a century of antipsychotics and still a central role for dopamine D2 receptors. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2003, 27 (7), 1081-1090. (Pubitemid 37464954)
3. Borgwardt, S.; McGuire, P.; Fusar-Poli, P., Gray matters!-mapping the transition to psychosis. Schizophr. Res., 2011, 133 (1-3), 63-67.
4. Haller, S.; Borgwardt, S. J.; Schindler, C.; Aston, J.; Radue, E. W.; Riecher-Rossler, A., Can cortical thickness asymmetry analysis contribute to detection of at-risk mental state and first-episode psychosis? A pilot study. Radiology, 2009, 250 (1), 212-221.
5. Fusar-Poli, P., Radua, J., McGuire, P., Borgwardt, S. , Neuroanatomical maps of psychosis onset: voxelwise meta-Analysis of antipschotic-naïve VBM studies. Schizophr. Bull., 2011, in press.
6. Fusar-Poli, P.; Smieskova, R.; Serafini, G.; Politi, P.; Borgwardt, S., Neuroanatomical markers of genetic liability to psychosis and first episode psychosis: A voxelwise meta-Analytical comparison. World J. Biol. Psychiatry, 2012.
7. Rothlisberger, M.; Riecher-Rossler, A.; Aston, J.; Fusar-Poli, P.; Radu, E. W.; Borgwardt, S., Cingulate volume abnormalities in emerging psychosis. Curr. Pharm. Des., 2012, 18 (4), 495-504.
8. Borgwardt, S. J.; Radue, E. W.; Gotz, K.; Aston, J.; Drewe, M.; Gschwandtner, U.; Haller, S.; Pfluger, M.; Stieglitz, R. D.; McGuire, P. K.; Riecher-Rossler, A., Radiological findings in individuals at high risk of psychosis. J. Neurol. Neurosurg. Psychiatry, 2006, 77 (2), 229-233. (Pubitemid 43220850)
9. Buehlmann, E.; Berger, G. E.; Aston, J.; Gschwandtner, U.; Pflueger, M. O.; Borgwardt, S. J.; Radue, E. W.; Riecher-Rossler, A., Hippocampus abnormalities in at risk mental states for psychosis? A cross-sectional high resolution region of interest magnetic resonance imaging study. J. Psychiatr. Res., 2010, 44 (7), 447-453.
10. Borgwardt, S. J.; Dickey, C.; Hulshoff Pol, H.; Whitford, T. J.; DeLisi, L. E., Workshop on defining the significance of progressive brain change in schizophrenia: December 12, 2008 American College of Neuropsychopharmacology (ACNP) all-day satellite, Scottsdale, Arizona. The rapporteurs' report. Schizophr. Res., 2009, 112 (1-3), 32-45.
11. Smieskova, R.; Fusar-Poli, P.; Aston, J.; Simon, A.; Bendfeldt, K.; Lenz, C.; Stieglitz, R. D.; McGuire, P.; Riecher-Rossler, A.; Borgwardt, S. J., Insular volume abnormalities associated with different transition probabilities to psychosis. Psychol. Med., 2012, 42 (8), 1613-1625.
12. Fusar-Poli, P.; Perez, J.; Broome, M.; Borgwardt, S.; Placentino, A.; Caverzasi, E.; Cortesi, M.; Veggiotti, P.; Politi, P.; Barale, F.; McGuire, P., Neurofunctional correlates of vulnerability to psychosis: a systematic review and meta-Analysis. Neurosci. Biobehav. Rev., 2007, 31 (4), 465-484. (Pubitemid 46527879)
13. Smieskova, R.; Fusar-Poli, P.; Riecher-Rossler, A.; Borgwardt, S., Neuroimaging and resilience factors -staging of the at-risk mental state? Curr. Pharm. Des., 2012, 18 (4), 416-421.
14. Howes, O. D.; Montgomery, A. J.; Asselin, M.; Murray, R.; Grasby, P.; McGuire, P., Molecular imaging studies of the striatal dopaminergic system in psychosis and predictions for the prodromal phase of psychosis. Br. J. Psychiatry, 2007, s51, s13-s18. (Pubitemid 350273183)
15. Stone, J. M., Imaging the glutamate system in humans: relevance to drug discovery for schizophrenia. Curr. Pharm. Des., 2009, 15 (22), 2594-2602.
16. Fusar-Poli, P.; McGuire, P.; Borgwardt, S., Mapping prodromal psychosis: a critical review of the literature. Eur. Psychiatry, 2011, in press.
17. Smieskova, R.; Fusar-Poli, P.; Allen, P.; Bendfeldt, K.; Stieglitz, R. D.; Drewe, J.; Radue, E. W.; McGuire, P. K.; Riecher-Rossler, A.; Borgwardt, S. J., The effects of antipsychotics on the brain: what have we learnt from structural imaging of schizophrenia?-A systematic review. Curr. Pharm. Des., 2009, 15 (22), 2535-2549.
18. Fusar-Poli, P.; Borgwardt, S.; Crescini, A.; Deste, G.; Kempton, M. J.; Lawrie, S.; Mc Guire, P.; Sacchetti, E., Neuroanatomy of vulnerability to psychosis: a voxel-based meta-Analysis. Neurosci. Biobehav. Rev., 2011, 35 (5), 1175-1185.
19. Smieskova, R.; Fusar-Poli, P.; Allen, P.; Bendfeldt, K.; Stieglitz, R.; Drewe, J.; Radue, E.; McGuire, P.; Riecher-Rössler, A.; Borgwardt, S., Neuroimaging predictors of transition to psychosis -A systematic review and meta-Analysis. Neurosci. Biobehav. Rev., 2010, 34 (8), 1207-1222.
20. Graeber, M. B., Changing face of microglia. Science, 2010, 330 (6005), 783-788.
21. Graeber, M. B.; Streit, W. J., Microglia: biology and pathology. Acta. Neuropathol., 2010, 119 (1), 89-105.
22. Doorduin, J.; de Vries, E. F.; Willemsen, A. T.; de Groot, J. C.; Dierckx, R. A.; Klein, H. C., Neuroinflammation in schizophrenia-related psychosis: a PET study. J. Nucl. Med., 2009, 50 (11), 1801-1807.
23. Takano, A.; Arakawa, R.; Ito, H.; Tateno, A.; Takahashi, H.; Matsumoto, R.; Okubo, Y.; Suhara, T., Peripheral benzodiazepine receptors in patients with chronic schizophrenia: a PET study with [11C]DAA1106. Int. J. Neuropsychopharmacol., 2010, 13 (7), 943-950.
24. van Berckel, B. N.; Bossong, M. G.; Boellaard, R.; Kloet, R.; Schuitemaker, A.; Caspers, E.; Luurtsema, G.; Windhorst, A. D.; Cahn, W.; Lammertsma, A. A.; Kahn, R. S., Microglia activation in recent-onset schizophrenia: a quantitative (R)-[11C]PK11195 positron emission tomography study. Biol. Psychiatry, 2008, 64 (9), 820-822.
25. Steiner, J.; Bielau, H.; Brisch, R.; Danos, P.; Ullrich, O.; Mawrin, C.; Bernstein, H. G.; Bogerts, B., Immunological aspects in the neurobiology of suicide: elevated microglial density in schizophrenia and depression is associated with suicide. J. Psychiatr. Res., 2008, 42 (2), 151-157. (Pubitemid 350061255)
26. Steiner, J.; Mawrin, C.; Ziegeler, A.; Bielau, H.; Ullrich, O.; Bernstein, H. G.; Bogerts, B., Distribution of HLA-DR-positive microglia in schizophrenia reflects impaired cerebral lateralization. Acta. Neuropathol., 2006, 112 (3), 305-316. (Pubitemid 44275885)
27. Tetreault, N. A.; Hakeem, A. Y.; Jiang, S.; Williams, B. A.; Allman, E.; Wold, B. J.; Allman, J. M., Microglia in the Cerebral Cortex in Autism. J. Autism. Dev. Disord., 2012.
28. Morgan, J. T.; Chana, G.; Pardo, C. A.; Achim, C.; Semendeferi, K.; Buckwalter, J.; Courchesne, E.; Everall, I. P., Microglial activation and increased microglial density observed in the dorsolateral prefrontal cortex in autism. Biol. Psychiatry, 2010, 68 (4), 368-376.
29. Derecki, N. C.; Cronk, J. C.; Lu, Z.; Xu, E.; Abbott, S. B.; Guyenet, P. G.; Kipnis, J., Wild-type microglia arrest pathology in a mouse model of Rett syndrome. Nature, 2012, 484 (7392), 105-109.
30. Liaury, K.; Miyaoka, T.; Tsumori, T.; Furuya, M.; Wake, R.; Ieda, M.; Tsuchie, K.; Taki, M.; Ishihara, K.; Tanra, A. J.; Horiguchi, J., Morphological features of microglial cells in the hippocampal dentate gyrus of Gunn rat: a possible schizophrenia animal model. J. Neuroinflammation, 2012, 9, 56.
31. Juckel, G.; Manitz, M. P.; Brune, M.; Friebe, A.; Heneka, M. T.; Wolf, R. J., Microglial activation in a neuroinflammational animal model of schizophrenia-A pilot study. Schizophr. Res., 2011, 131 (1-3), 96-100.
32. Pocock, J. M.; Kettenmann, H., Neurotransmitter receptors on microglia. Trends Neurosci., 2007, 30 (10), 527-535. (Pubitemid 47513237)
33. Kettenmann, H.; Hanisch, U. K.; Noda, M.; Verkhratsky, A., Physiology of microglia. Physiol. Rev., 2011, 91 (2), 461-553.
34. Mastroeni, D.; Grover, A.; Leonard, B.; Joyce, J. N.; Coleman, P. D.; Kozik, B.; Bellinger, D. L.; Rogers, J., Microglial responses to dopamine in a cell culture model of Parkinson's disease. Neurobiol. Aging, 2009, 30 (11), 1805-1817.
35. Farber, K.; Pannasch, U.; Kettenmann, H., Dopamine and noradrenaline control distinct functions in rodent microglial cells. Mol. Cell Neurosci., 2005, 29 (1), 128-138. (Pubitemid 40613058)
36. Kato, T.; Mizoguchi, Y.; Monji, A.; Horikawa, H.; Suzuki, S. O.; Seki, Y.; Iwaki, T.; Hashioka, S.; Kanba, S., Inhibitory effects of aripiprazole on interferon-gamma-induced microglial activation via intracellular Ca2+ regulation in vitro. J. Neurochem., 2008, 106 (2), 815-825.
37. Krabbe, G.; Matyash, V.; Pannasch, U.; Mamer, L.; Boddeke, H. W.; Kettenmann, H., Activation of serotonin receptors promotes microglial injury-induced motility but attenuates phagocytic activity. Brain Behav. Immun., 2012, 26 (3), 419-428.
38. Tynan, R. J.; Weidenhofer, J.; Hinwood, M.; Cairns, M. J.; Day, T. A.; Walker, F. R., A comparative examination of the anti-inflammatory effects of SSRI and SNRI antidepressants on LPS stimulated microglia. Brain Behav. Immun., 2012, 26 (3), 469-479.
39. Sara, S. J., The locus coeruleus and noradrenergic modulation of cognition. Nat. Rev. Neurosci., 2009, 10 (3), 211-223.
40. Mori, K.; Ozaki, E.; Zhang, B.; Yang, L.; Yokoyama, A.; Takeda, I.; Maeda, N.; Sakanaka, M.; Tanaka, J., Effects of norepinephrine on rat cultured microglial cells that express alpha1, alpha2, beta1 and beta2 adrenergic receptors. Neuropharmacology, 2002, 43 (6), 1026-1034. (Pubitemid 35341238)
41. Tanaka, K. F.; Kashima, H.; Suzuki, H.; Ono, K.; Sawada, M., Existence of functional beta1-And beta2-Adrenergic receptors on microglia. J. Neurosci. Res., 2002, 70 (2), 232-237.
42. Schlachetzki, J. C.; Fiebich, B. L.; Haake, E.; de Oliveira, A. C.; Candelario-Jalil, E.; Heneka, M. T.; Hull, M., Norepinephrine enhances the LPS-induced expression of COX-2 and secretion of PGE2 in primary rat microglia. J. Neuroinflammation, 2010, 7, 2.
43. Morioka, N.; Tanabe, H.; Inoue, A.; Dohi, T.; Nakata, Y., Noradrenaline reduces the ATP-stimulated phosphorylation of p38 MAP kinase via betaadrenergic receptors-cAMP-protein kinase A-dependent mechanism in cultured rat spinal microglia. Neurochem. Int., 2009, 55 (4), 226-234.
44. Dello Russo, C.; Boullerne, A. I.; Gavrilyuk, V.; Feinstein, D. L., Inhibition of microglial inflammatory responses by norepinephrine: effects on nitric oxide and interleukin-1beta production. J. Neuroinflammation, 2004, 1 (1), 9.
45. McNamee, E. N.; Ryan, K. M.; Kilroy, D.; Connor, T. J., Noradrenaline induces IL-1ra and IL-1 type II receptor expression in primary glial cells and protects against IL-1beta-induced neurotoxicity. Eur. J. Pharmacol., 2010, 626 (2-3), 219-228.
46. Kong, Y.; Ruan, L.; Qian, L.; Liu, X.; Le, Y., Norepinephrine promotes microglia to uptake and degrade amyloid beta peptide through upregulation of mouse formyl peptide receptor 2 and induction of insulin-degrading enzyme. J. Neurosci., 2010, 30 (35), 11848-11857.
47. Heneka, M. T.; Nadrigny, F.; Regen, T.; Martinez-Hernandez, A.; Dumitrescu-Ozimek, L.; Terwel, D.; Jardanhazi-Kurutz, D.; Walter, J.; Kirchhoff, F.; Hanisch, U. K.; Kummer, M. P., Locus ceruleus controls Alzheimer's disease pathology by modulating microglial functions through norepinephrine. Proc. Natl. Acad. Sci. USA, 2010, 107 (13), 6058-6063.
48. Kalinin, S.; Gavrilyuk, V.; Polak, P. E.; Vasser, R.; Zhao, J.; Heneka, M. T.; Feinstein, D. L., Noradrenaline deficiency in brain increases beta-Amyloid plaque burden in an animal model of Alzheimer's disease. Neurobiol. Aging, 2007, 28 (8), 1206-1214. (Pubitemid 46810064)
49. Yang, J. H.; Lee, E. O.; Kim, S. E.; Suh, Y. H.; Chong, Y. H., Norepinephrine differentially modulates the innate inflammatory response provoked by amyloid-beta peptide via action at beta-Adrenoceptors and activation of cAMP/PKA pathway in human THP-1 macrophages. Exp. Neurol., 2012, 236 (2), 199-206.
50. Steininger, T. S.; Stutz, H.; Kerschbaum, H. H., Beta-Adrenergic stimulation suppresses phagocytosis via Epac activation in murine microglial cells. Brain Res., 2011, 1407, 1-12.
51. Picciotto, M. R.; Caldarone, B. J.; King, S. L.; Zachariou, V., Nicotinic receptors in the brain. Links between molecular biology and behavior. Neuropsychopharmacology, 2000, 22 (5), 451-465. (Pubitemid 30145613)
52. De Simone, R.; Ajmone-Cat, M. A.; Carnevale, D.; Minghetti, L., Activation of alpha7 nicotinic acetylcholine receptor by nicotine selectively up-regulates cyclooxygenase-2 and prostaglandin E2 in rat microglial cultures. J. Neuroinflammation, 2005, 2 (1), 4.
53. Liu, J.; McGlinn, A. M.; Fernandes, A.; Milam, A. H.; Strang, C. E.; Andison, M. E.; Lindstrom, J. M.; Keyser, K. T.; Stone, R. A., Nicotinic acetylcholine receptor subunits in rhesus monkey retina. Invest. Ophthalmol. Vis. Sci., 2009, 50 (3), 1408-1415.
54. Rock, R. B.; Gekker, G.; Aravalli, R. N.; Hu, S.; Sheng, W. S.; Peterson, P. K., Potentiation of HIV-1 expression in microglial cells by nicotine: involvement of transforming growth factor-beta 1. J. Neuroimmune Pharmacol., 2008, 3 (3), 143-149.
55. Suzuki, T.; Hide, I.; Matsubara, A.; Hama, C.; Harada, K.; Miyano, K.; Andra, M.; Matsubayashi, H.; Sakai, N.; Kohsaka, S.; Inoue, K.; Nakata, Y., Microglial alpha7 nicotinic acetylcholine receptors drive a phospholipase C/IP3 pathway and modulate the cell activation toward a neuroprotective role. J. Neurosci. Res., 2006, 83 (8), 1461-1470. (Pubitemid 43844991)
56. Wang, H.; Yu, M.; Ochani, M.; Amella, C. A.; Tanovic, M.; Susarla, S.; Li, J. H.; Yang, H.; Ulloa, L.; Al-Abed, Y.; Czura, C. J.; Tracey, K. J., Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation. Nature, 2003, 421 (6921), 384-388. (Pubitemid 36157937)
57. van Gool, W. A.; van de Beek, D.; Eikelenboom, P., Systemic infection and delirium: when cytokines and acetylcholine collide. Lancet, 2010, 375 (9716), 773-775.
58. Dingledine, R.; Borges, K.; Bowie, D.; Traynelis, S. F., The glutamate receptor ion channels. Pharmacol. Rev., 1999, 51 (1), 7-61. (Pubitemid 29113865)
59. Ferraguti, F.; Shigemoto, R., Metabotropic glutamate receptors. Cell Tissue Res., 2006, 326 (2), 483-504. (Pubitemid 44435821)
60. Hagino, Y.; Kariura, Y.; Manago, Y.; Amano, T.; Wang, B.; Sekiguchi, M.; Nishikawa, K.; Aoki, S.; Wada, K.; Noda, M., Heterogeneity and potentiation of AMPA type of glutamate receptors in rat cultured microglia. Glia, 2004, 47 (1), 68-77. (Pubitemid 38879707)
61. Noda, M.; Nakanishi, H.; Nabekura, J.; Akaike, N., AMPA-kainate subtypes of glutamate receptor in rat cerebral microglia. J. Neurosci., 2000, 20 (1), 251-258. (Pubitemid 30220512)
62. Murugan, M.; Sivakumar, V.; Lu, J.; Ling, E. A.; Kaur, C., Expression of Nmethyl D-Aspartate receptor subunits in amoeboid microglia mediates production of nitric oxide via NF-kappaB signaling pathway and oligodendrocyte cell death in hypoxic postnatal rats. Glia, 2011, 59 (4), 521-539.
63. Daulhac, L.; Maffre, V.; Mallet, C.; Etienne, M.; Privat, A. M.; Kowalski-Chauvel, A.; Seva, C.; Fialip, J.; Eschalier, A., Phosphorylation of spinal Nmethyl-d-Aspartate receptor NR1 subunits by extracellular signal-regulated kinase in dorsal horn neurons and microglia contributes to diabetes-induced painful neuropathy. Eur. J. Pain, 2011, 15 (2), 169 e161-169 e112.
64. Biber, K.; Laurie, D. J.; Berthele, A.; Sommer, B.; Tolle, T. R.; Gebicke-Harter, P. J.; van Calker, D.; Boddeke, H. W., Expression and signaling of group I metabotropic glutamate receptors in astrocytes and microglia. J. Neurochem., 1999, 72 (4), 1671-1680. (Pubitemid 29140843)
65. Taylor, D. L.; Diemel, L. T.; Cuzner, M. L.; Pocock, J. M., Activation of group II metabotropic glutamate receptors underlies microglial reactivity and neurotoxicity following stimulation with chromogranin A, a peptide upregulated in Alzheimer's disease. J. Neurochem., 2002, 82 (5), 1179-1191. (Pubitemid 34966630)
66. Taylor, D. L.; Diemel, L. T.; Pocock, J. M., Activation of microglial group III metabotropic glutamate receptors protects neurons against microglial neurotoxicity. J. Neurosci., 2003, 23 (6), 2150-2160. (Pubitemid 36368903)
67. Liu, G. J.; Nagarajah, R.; Banati, R. B.; Bennett, M. R., Glutamate induces directed chemotaxis of microglia. Eur. J. Neurosci., 2009, 29 (6), 1108-1118.
68. Christensen, R. N.; Ha, B. K.; Sun, F.; Bresnahan, J. C.; Beattie, M. S., Kainate induces rapid redistribution of the actin cytoskeleton in ameboid microglia. J. Neurosci. Res., 2006, 84 (1), 170-181. (Pubitemid 44023072)
69. Farso, M. C.; O'Shea, R. D.; Beart, P. M., Evidence group I mGluR drugs modulate the activation profile of lipopolysaccharide-exposed microglia in culture. Neurochem. Res., 2009, 34 (10), 1721-1728.
70. Lee, A.; Pow, D. V., Astrocytes: Glutamate transport and alternate splicing of transporters. Int. J. Biochem. Cell Biol., 2010, 42 (12), 1901-1906.
71. Beschorner, R.; Dietz, K.; Schauer, N.; Mittelbronn, M.; Schluesener, H. J.; Trautmann, K.; Meyermann, R.; Simon, P., Expression of EAAT1 reflects a possible neuroprotective function of reactive astrocytes and activated microglia following human traumatic brain injury. Histol. Histopathol., 2007, 22 (5), 515-526. (Pubitemid 46647265)
72. Beschorner, R.; Simon, P.; Schauer, N.; Mittelbronn, M.; Schluesener, H. J.; Trautmann, K.; Dietz, K.; Meyermann, R., Reactive astrocytes and activated microglial cells express EAAT1, but not EAAT2, reflecting a neuroprotective potential following ischaemia. Histopathology, 2007, 50 (7), 897-910. (Pubitemid 46850077)
73. Vallat-Decouvelaere, A. V.; Chretien, F.; Gras, G.; Le Pavec, G.; Dormont, D.; Gray, F., Expression of excitatory amino acid transporter-1 in brain macrophages and microglia of HIV-infected patients. A neuroprotective role for activated microglia? J. Neuropathol. Exp. Neurol., 2003, 62 (5), 475-485. (Pubitemid 36560189)
74. Lopez-Redondo, F.; Nakajima, K.; Honda, S.; Kohsaka, S., Glutamate transporter GLT-1 is highly expressed in activated microglia following facial nerve axotomy. Brain Res. Mol. Brain Res., 2000, 76 (2), 429-435. (Pubitemid 30179784)
75. van Landeghem, F. K.; Stover, J. F.; Bechmann, I.; Bruck, W.; Unterberg, A.; Buhrer, C.; von Deimling, A., Early expression of glutamate transporter proteins in ramified microglia after controlled cortical impact injury in the rat. Glia, 2001, 35 (3), 167-179. (Pubitemid 32827760)
76. Xing, H. Q.; Hayakawa, H.; Gelpi, E.; Kubota, R.; Budka, H.; Izumo, S., Reduced expression of excitatory amino acid transporter 2 and diffuse microglial activation in the cerebral cortex in AIDS cases with or without HIV encephalitis. J. Neuropathol. Exp. Neurol., 2009, 68 (2), 199-209.
77. Kraeplin, E., Dementia Praecox and Paraphrenia. E&S Livingstone: Edinburgh, 1919.
78. Kim, J. S.; Kornhuber, H. H.; Schmid-Burgk, W.; Holzmuller, B., Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia. Neurosci. Lett., 1980, 20 (3), 379-382. (Pubitemid 11160082)
79. Goff, D. C.; Coyle, J. T., The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am. J. Psychiatry, 2001, 158 (9), 1367-1377. (Pubitemid 32847232)
80. Keshavan, M. S.; Nasrallah, H. A.; Tandon, R., Schizophrenia, "Just the Facts" 6. Moving ahead with the schizophrenia concept: from the elephant to the mouse. Schizophr. Res., 2011, 127 (1-3), 3-13.
81. Monji, A.; Kato, T. A.; Mizoguchi, Y.; Horikawa, H.; Seki, Y.; Kasai, M.; Yamauchi, Y.; Yamada, S.; Kanba, S., Neuroinflammation in schizophrenia especially focused on the role of microglia. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2011.
82. Kato, T. A.; Monji, A.; Mizoguchi, Y.; Hashioka, S.; Horikawa, H.; Seki, Y.; Kasai, M.; Utsumi, H.; Kanba, S., Anti-Inflammatory properties of antipsychotics via microglia modulations: are antipsychotics a 'fire extinguisher' in the brain of schizophrenia? Mini Rev. Med. Chem., 2011, 11 (7), 565-574.
83. Monji, A.; Kato, T.; Kanba, S., Cytokines and schizophrenia: Microglia hypothesis of schizophrenia. Psychiatry Clin. Neurosci., 2009, 63 (3), 257-265.
84. Howes, O.; Bose, S.; Turkheimer, F.; Valli, I.; Egerton, A.; Stahl, D.; Valmaggia, L.; Allen, P.; Murray, R.; McGuire, P., Progressive increase in striatal dopamine synthesis capacity as patients develop psychosis: a PET study. Mol. Psychiatry, 2011.
85. Kowalski, J.; Labuzek, K.; Herman, Z. S., Flupentixol and trifluperidol reduce secretion of tumor necrosis factor-Alpha and nitric oxide by rat microglial cells. Neurochem. Int., 2003, 43, 173-178. (Pubitemid 36287336)
86. Kowalski, J.; Labuzek, K.; Herman, Z. S., Flupentixol and trifluperidol reduce interleukin-1 beta and interleukin-2 release by rat mixed glial and microglial cell cultures. Pol. J. Pharmacol., 2004, 56, 563-570. (Pubitemid 40123656)
87. Labuzek, K.; Kowalski, J.; Gabryel, B.; Herman, Z. S., Chlorpromazine and loxapine reduce interleukin-1beta and interleukin-2 release by rat mixed glial and microglial cell cultures. Eur. Neuropsychopharmacol., 2005, 15, 23-30. (Pubitemid 39574396)
88. Hou, Y.; Wu, C. F.; Yang, J. Y.; He, X.; Bi, X. L.; Yu, L.; Guo, T., Effects of clozapine, olanzapine and haloperidol on nitric oxide production by lipopolysaccharide-Activated N9 cells. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2006, 30 (8), 1523-1528. (Pubitemid 44634941)
89. Kato, T.; Monji, A.; Hashioka, S.; Kanba, S., Risperidone significantly inhibits interferon-gamma-induced microglial activation in vitro. Schizophr. Res., 2007, 92 (1-3), 108-115. (Pubitemid 46561234)
90. Bian, Q.; Kato, T.; Monji, A.; Hashioka, S.; Mizoguchi, Y.; Horikawa, H.; Kanba, S., The effect of atypical antipsychotics, perospirone, ziprasidone and quetiapine on microglial activation induced by interferon-gamma. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2008, 32 (1), 42-48.
91. Zheng, L. T.; Hwang, J.; Ock, J.; Lee, M. G.; Lee, W. H.; Suk, K., The antipsychotic spiperone attenuates inflammatory response in cultured microglia via the reduction of proinflammatory cytokine expression and nitric oxide production. J. Neurochem., 2008, 107 (5), 1225-1235.
92. Shapiro, D. A.; Renock, S.; Arrington, E.; Chiodo, L. A.; Liu, L. X.; Sibley, D. R.; Roth, B. L.; Mailman, R., Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology, 2003, 28 (8), 1400-1411. (Pubitemid 41070874)
93. Burris, K. D.; Molski, T. F.; Xu, C.; Ryan, E.; Tottori, K.; Kikuchi, T.; Yocca, F. D.; Molinoff, P. B., Aripiprazole, a novel antipsychotic, is a highaffinity partial agonist at human dopamine D2 receptors. J. Pharmacol. Exp. Ther., 2002, 302 (1), 381-389. (Pubitemid 34680462)
94. Kato, T. A.; Monji, A.; Yasukawa, K.; Mizoguchi, Y.; Horikawa, H.; Seki, Y.; Hashioka, S.; Han, Y. H.; Kasai, M.; Sonoda, N.; Hirata, E.; Maeda, Y.; Inoguchi, T.; Utsumi, H.; Kanba, S., Aripiprazole inhibits superoxide generation from phorbol-myristate-Acetate (PMA)-stimulated microglia in vitro: implication for antioxidative psychotropic actions via microglia. Schizophr. Res., 2011, 129 (2-3), 172-182.
95. Hu, X.; Zhou, H.; Zhang, D.; Yang, S.; Qian, L.; Wu, H. M.; Chen, P. S.; Wilson, B.; Gao, H. M.; Lu, R. B.; Hong, J. S., Clozapine protects dopaminergic neurons from inflammation-induced damage by inhibiting microglial overactivation. J. Neuroimmune Pharmacol., 2012, 7 (1), 187-201.
96. Xiao, L.; Xu, H.; Zhang, Y.; Wei, Z.; He, J.; Jiang, W.; Li, X.; Dyck, L. E.; Devon, R. M.; Deng, Y.; Li, X. M., Quetiapine facilitates oligodendrocyte development and prevents mice from myelin breakdown and behavioral changes. Mol. Psychiatry, 2008, 13 (7), 697-708. (Pubitemid 351861531)
97. Meyer, U.; Nyffeler, M.; Yee, B. K.; Knuesel, I.; Feldon, J., Adult brain and behavioral pathological markers of prenatal immune challenge during early/middle and late fetal development in mice. Brain Behav. Immun., 2008, 22 (4), 469-486. (Pubitemid 351451821)
98. Zhang, Y.; Xu, H.; Jiang, W.; Xiao, L.; Yan, B.; He, J.; Wang, Y.; Bi, X.; Li, X.; Kong, J.; Li, X. M., Quetiapine alleviates the cuprizone-induced white matter pathology in the brain of C57BL/6 mouse. Schizophr. Res., 2008, 106 (2-3), 182-191.
99. Zhang, Y.; Zhang, H.; Wang, L.; Jiang, W.; Xu, H.; Xiao, L.; Bi, X.; Wang, J.; Zhu, S.; Zhang, R.; He, J.; Tan, Q.; Zhang, D.; Kong, J.; Li, X. M., Quetiapine enhances oligodendrocyte regeneration and myelin repair after cuprizone-induced demyelination. Schizophr. Res., 2012, 138 (1), 8-17.
100. Macdowell, K. S.; Garcia-Bueno, B.; Madrigal, J. L.; Parellada, M.; Arango, C.; Mico, J. A.; Leza, J. C., Risperidone normalizes increased inflammatory parameters and restores anti-inflammatory pathways in a model of neuroinflammation. Int. J. Neuropsychopharmacol., 2011, 1-15.
101. Meyer, U.; Spoerri, E.; Yee, B. K.; Schwarz, M. J.; Feldon, J., Evaluating early preventive antipsychotic and antidepressant drug treatment in an infection-based neurodevelopmental mouse model of schizophrenia. Schizophr. Bull., 2010, 36 (3), 607-623.
102. Anisman, H., Cascading effects of stressors and inflammatory immune system activation: implications for major depressive disorder. J. Psychiatry Neurosci., 2009, 34 (1), 4-20.
103. Miller, A. H.; Maletic, V.; Raison, C. L., Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol, Psychiatry, 2009, 65 (9), 732-741.
104. Muller, N.; Schwarz, M. J., The immune-mediated alteration of serotonin and glutamate: towards an integrated view of depression. Mol. Psychiatry, 2007, 12 (11), 988-1000. (Pubitemid 350006207)
105. Raison, C. L.; Capuron, L.; Miller, A. H., Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol., 2006, 27 (1), 24-31. (Pubitemid 43083561)
106. Schiepers, O. J.; Wichers, M. C.; Maes, M., Cytokines and major depression. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2005, 29 (2), 201-217. (Pubitemid 40202906)
107. Dowlati, Y.; Herrmann, N.; Swardfager, W.; Liu, H.; Sham, L.; Reim, E. K.; Lanctot, K. L., A meta-Analysis of cytokines in major depression. Biol. Psychiatry, 2009, 67 (5), 446-457.
108. Liu, Y.; Ho, R. C.; Mak, A., Interleukin (IL)-6, tumour necrosis factor alpha (TNF-Alpha) and soluble interleukin-2 receptors (sIL-2R) are elevated in patients with major depressive disorder: A meta-Analysis and metaregression. J. Affect. Disord., 2012, 139 (3), 230-239.
109. Hashioka, S.; Klegeris, A.; Monji, A.; Kato, T.; Sawada, M.; McGeer, P. L.; Kanba, S., Antidepressants inhibit interferon-gamma-induced microglial production of IL-6 and nitric oxide. Exp. Neurol., 2007, 206 (1), 33-42. (Pubitemid 46935120)
110. Hwang, J.; Zheng, L. T.; Ock, J.; Lee, M. G.; Kim, S. H.; Lee, H. W.; Lee, W. H.; Park, H. C.; Suk, K., Inhibition of glial inflammatory activation and neurotoxicity by tricyclic antidepressants. Neuropharmacology, 2008, 55 (5), 826-834.
111. Lim, C. M.; Kim, S. W.; Park, J. Y.; Kim, C.; Yoon, S. H.; Lee, J. K., Fluoxetine affords robust neuroprotection in the postischemic brain via its anti-inflammatory effect. J. Neurosci. Res., 2009, 87 (4), 1037-1045.
112. Obuchowicz, E.; Kowalski, J.; Labuzek, K.; Krysiak, R.; Pendzich, J.; Herman, Z. S., Amitriptyline and nortriptyline inhibit interleukin-1 release by rat mixed glial and microglial cell cultures. Int. J. Neuropsychopharmacol., 2006, 9 (1), 27-35. (Pubitemid 43068332)
113. Vollmar, P.; Haghikia, A.; Dermietzel, R.; Faustmann, P. M., Venlafaxine exhibits an anti-inflammatory effect in an inflammatory co-culture model. Int. J. Neuropsychopharmacol., 2008, 11 (1), 111-117.
114. Liu, D.; Wang, Z.; Liu, S.; Wang, F.; Zhao, S.; Hao, A., Anti-inflammatory effects of fluoxetine in lipopolysaccharide(LPS)-stimulated microglial cells. Neuropharmacology, 2011, 61 (4), 592-599.
115. O'Connor, J. C.; Lawson, M. A.; Andre, C.; Moreau, M.; Lestage, J.; Castanon, N.; Kelley, K. W.; Dantzer, R., Lipopolysaccharide-induced depressive-like behavior is mediated by indoleamine 2,3-dioxygenase activation in mice. Mol. Psychiatry, 2009, 14 (5), 511-522.
116. Hurlock, E. C. t., Interferons: potential roles in affect. Med. Hypotheses, 2001, 56 (5), 558-566.
117. Schwarz, M. J.; Chiang, S.; Muller, N.; Ackenheil, M., T-helper-1 and Thelper-2 responses in psychiatric disorders. Brain Behav. Immun., 2001, 15 (4), 340-370. (Pubitemid 34044520)
118. Schwarz, M. J.; Muller, N.; Riedel, M.; Ackenheil, M., The Th2-hypothesis of schizophrenia: a strategy to identify a subgroup of schizophrenia caused by immune mechanisms. Med. Hypotheses, 2001, 56 (4), 483-486. (Pubitemid 32397883)
119. Horikawa, H.; Kato, T. A.; Mizoguchi, Y.; Monji, A.; Seki, Y.; Ohkuri, T.; Gotoh, L.; Yonaha, M.; Ueda, T.; Hashioka, S.; Kanba, S., Inhibitory effects of SSRIs on IFN-gamma induced microglial activation through the regulation of intracellular calcium. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2010, 34 (7), 1306-1316.
120. Chung, E. S.; Chung, Y. C.; Bok, E.; Baik, H. H.; Park, E. S.; Park, J. Y.; Yoon, S. H.; Jin, B. K., Fluoxetine prevents LPS-induced degeneration of nigral dopaminergic neurons by inhibiting microglia-mediated oxidative stress. Brain Res., 2010, 1363, 143-150.
121. Chung, Y. C.; Kim, S. R.; Park, J. Y.; Chung, E. S.; Park, K. W.; Won, S. Y.; Bok, E.; Jin, M.; Park, E. S.; Yoon, S. H.; Ko, H. W.; Kim, Y. S.; Jin, B. K., Fluoxetine prevents MPTP-induced loss of dopaminergic neurons by inhibiting microglial activation. Neuropharmacology, 2011, 60 (6), 963-974.
122. Tyring, S.; Gottlieb, A.; Papp, K.; Gordon, K.; Leonardi, C.; Wang, A.; Lalla, D.; Woolley, M.; Jahreis, A.; Zitnik, R.; Cella, D.; Krishnan, R., Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet, 2006, 367 (9504), 29-35. (Pubitemid 43038667)
123. Uguz, F.; Akman, C.; Kucuksarac, S.; Tufekci, O., Anti-tumor necrosis factor-Alpha therapy is associated with less frequent mood and anxiety disorders in patients with rheumatoid arthritis. Psychiatry Clin. Neurosci., 2009, 63 (1), 50-55.
124. Vezzani, A.; Aronica, E.; Mazarati, A.; Pittman, Q. J., Epilepsy and brain inflammation. Exp. Neurol., 2011.
125. Choi, J.; Nordli, D. R., Jr.; Alden, T. D.; DiPatri, A., Jr.; Laux, L.; Kelley, K.; Rosenow, J.; Schuele, S. U.; Rajaram, V.; Koh, S., Cellular injury and neuroinflammation in children with chronic intractable epilepsy. J. Neuroinflammation, 2009, 6, 38.
126. Najjar, S.; Pearlman, D.; Miller, D. C.; Devinsky, O., Refractory epilepsy associated with microglial activation. Neurologist, 2011, 17 (5), 249-254.
127. Kan, A. A.; de Jager, W.; de Wit, M.; Heijnen, C.; van Zuiden, M.; Ferrier, C.; van Rijen, P.; Gosselaar, P.; Hessel, E.; van Nieuwenhuizen, O.; de Graan, P. N., Protein expression profiling of inflammatory mediators in human temporal lobe epilepsy reveals co-Activation of multiple chemokines and cytokines. J. Neuroinflammation, 2012, 9 (1), 207.
128. Avignone, E.; Ulmann, L.; Levavasseur, F.; Rassendren, F.; Audinat, E., Status epilepticus induces a particular microglial activation state characterized by enhanced purinergic signaling. J. Neurosci, 2008, 28 (37), 9133-9144.
129. Minami, M.; Kuraishi, Y.; Satoh, M., Effects of kainic acid on messenger RNA levels of IL-1 beta, IL-6, TNF alpha and LIF in the rat brain. Biochem. Biophys. Res. Commun., 1991, 176 (2), 593-598.
130. De Simoni, M. G.; Perego, C.; Ravizza, T.; Moneta, D.; Conti, M.; Marchesi, F.; De Luigi, A.; Garattini, S.; Vezzani, A., Inflammatory cytokines and related genes are induced in the rat hippocampus by limbic status epilepticus. Eur. J. Neurosci., 2000, 12 (7), 2623-2633. (Pubitemid 30497055)
131. Turrin, N. P.; Rivest, S., Innate immune reaction in response to seizures: implications for the neuropathology associated with epilepsy. Neurobiol. Dis., 2004, 16 (2), 321-334. (Pubitemid 38757314)
132. Xiong, Z. Q.; Qian, W.; Suzuki, K.; McNamara, J. O., Formation of complement membrane attack complex in mammalian cerebral cortex evokes seizures and neurodegeneration. J. Neurosci., 2003, 23 (3), 955-960. (Pubitemid 36206186)
133. Riazi, K.; Galic, M. A.; Kuzmiski, J. B.; Ho, W.; Sharkey, K. A.; Pittman, Q. J., Microglial activation and TNFalpha production mediate altered CNS excitability following peripheral inflammation. Proc. Natl. Acad. Sci. USA, 2008, 105 (44), 17151-17156.
134. Suh, H. S.; Choi, S.; Khattar, P.; Choi, N.; Lee, S. C., Histone deacetylase inhibitors suppress the expression of inflammatory and innate immune response genes in human microglia and astrocytes. J. Neuroimmune Pharmacol., 2010, 5 (4), 521-532.
135. Peng, G. S.; Li, G.; Tzeng, N. S.; Chen, P. S.; Chuang, D. M.; Hsu, Y. D.; Yang, S.; Hong, J. S., Valproate pretreatment protects dopaminergic neurons from LPS-induced neurotoxicity in rat primary midbrain cultures: role of microglia. Brain Res. Mol. Brain Res., 2005, 134 (1), 162-169. (Pubitemid 40403648)
136. Chen, P. S.; Wang, C. C.; Bortner, C. D.; Peng, G. S.; Wu, X.; Pang, H.; Lu, R. B.; Gean, P. W.; Chuang, D. M.; Hong, J. S., Valproic acid and other histone deacetylase inhibitors induce microglial apoptosis and attenuate lipopolysaccharide-induced dopaminergic neurotoxicity. Neuroscience, 2007, 149 (1), 203-212. (Pubitemid 47488650)
137. Dragunow, M.; Greenwood, J. M.; Cameron, R. E.; Narayan, P. J.; O'Carroll, S. J.; Pearson, A. G.; Gibbons, H. M., Valproic acid induces caspase 3-mediated apoptosis in microglial cells. Neuroscience, 2006, 140 (4), 1149-1156. (Pubitemid 43928264)
138. Smith, A. M.; Gibbons, H. M.; Dragunow, M., Valproic acid enhances microglial phagocytosis of amyloid-beta(1-42). Neuroscience, 2010, 169 (1), 505-515.
139. Xie, N.; Wang, C.; Lin, Y.; Li, H.; Chen, L.; Zhang, T.; Sun, Y.; Zhang, Y.; Yin, D.; Chi, Z., The role of p38 MAPK in valproic acid induced microglia apoptosis. Neurosci. Lett., 2010, 482 (1), 51-56.
140. Gibbons, H. M.; Smith, A. M.; Teoh, H. H.; Bergin, P. M.; Mee, E. W.; Faull, R. L.; Dragunow, M., Valproic acid induces microglial dysfunction, not apoptosis, in human glial cultures. Neurobiol. Dis., 2011, 41 (1), 96-103.
141. Xuan, A.; Long, D.; Li, J.; Ji, W.; Hong, L.; Zhang, M.; Zhang, W., Neuroprotective effects of valproic acid following transient global ischemia in rats. Life Sci., 2012, 90 (11-12), 463-468.
142. Kim, H. J.; Rowe, M.; Ren, M.; Hong, J. S.; Chen, P. S.; Chuang, D. M., Histone deacetylase inhibitors exhibit anti-inflammatory and neuroprotective effects in a rat permanent ischemic model of stroke: multiple mechanisms of action. J. Pharmacol. Exp. Ther., 2007, 321 (3), 892-901. (Pubitemid 46762687)
143. Zhang, Z.; Zhang, Z. Y.; Fauser, U.; Schluesener, H. J., Valproic acid attenuates inflammation in experimental autoimmune neuritis. Cell Mol. Life Sci., 2008, 65 (24), 4055-4065.
144. Yokoyama, H.; Yano, R.; Kuroiwa, H.; Tsukada, T.; Uchida, H.; Kato, H.; Kasahara, J.; Araki, T., Therapeutic effect of a novel anti-parkinsonian agent zonisamide against MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) neurotoxicity in mice. Metab. Brain Dis., 2010, 25 (3), 305-313.
145. Ha, K. Y.; Kim, Y. H.; Rhyu, K. W.; Kwon, S. E., Pregabalin as a neuroprotector after spinal cord injury in rats. Eur. Spine J., 2008, 17 (6), 864-872.
146. Yang, J. L.; Xu, B.; Li, S. S.; Zhang, W. S.; Xu, H.; Deng, X. M.; Zhang, Y. Q., Gabapentin reduces CX3CL1 signaling and blocks spinal microglial activation in monoarthritic rats. Mol. Brain, 2012, 5 (1), 18.
147. Morimoto, S.; Ito, M.; Oda, S.; Sugiyama, A.; Kuroda, M.; Adachi-Akahane, S., Spinal mechanism underlying the antiallodynic effect of gabapentin studied in the mouse spinal nerve ligation model. J. Pharmacol. Sci., 2012, 118 (4), 455-466.
148. Black, J. A.; Liu, S.; Waxman, S. G., Sodium channel activity modulates multiple functions in microglia. Glia, 2009, 57 (10), 1072-1081.
149. Craner, M. J.; Damarjian, T. G.; Liu, S.; Hains, B. C.; Lo, A. C.; Black, J. A.; Newcombe, J.; Cuzner, M. L.; Waxman, S. G., Sodium channels contribute to microglia/macrophage activation and function in EAE and MS. Glia, 2005, 49 (2), 220-229. (Pubitemid 40188501)
150. Black, J. A.; Liu, S.; Carrithers, M.; Carrithers, L. M.; Waxman, S. G., Exacerbation of experimental autoimmune encephalomyelitis after withdrawal of phenytoin and carbamazepine. Ann. Neurol., 2007, 62 (1), 21-33. (Pubitemid 47235277)
151. Jeon, H. J.; Han, S. R.; Park, M. K.; Yang, K. Y.; Bae, Y. C.; Ahn, D. K., A novel trigeminal neuropathic pain model: Compression of the trigeminal nerve root produces prolonged nociception in rats. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2012, 38 (2), 149-158.
152. Ventriglio, A.; Vincenti, A.; Centorrino, F.; Talamo, A.; Fitzmaurice, G.; Baldessarini, R. J., Use of mood stabilizers for hospitalized psychotic and bipolar disorder patients. Int. Clin. Psychopharmacol., 2011, 26 (2), 88-95.
153. Sim, K.; Yong, K. H.; Chan, Y. H.; Tor, P. C.; Xiang, Y. T.; Wang, C. Y.; Lee, E. H.; Fujii, S.; Yang, S. Y.; Chong, M. Y.; Ungvari, G. S.; Si, T.; He, Y. L.; Chung, E. K.; Chee, K. Y.; Trivedi, J.; Udomratn, P.; Shinfuku, N.; Kua, E. H.; Tan, C. H.; Sartorius, N.; Baldessarini, R. J., Adjunctive mood stabilizer treatment for hospitalized schizophrenia patients: Asia psychotropic prescription study (2001-2008). Int. J. Neuropsychopharmacol., 2011, 14 (9), 1157-1164.
154. Pickar, D.; Vinik, J.; Bartko, J. J., Pharmacotherapy of schizophrenic patients: preponderance of off-label drug use. PLoS One, 2008, 3 (9), e3150.
155. Thies-Flechtner, K.; Muller-Oerlinghausen, B.; Seibert, W.; Walther, A.; Greil, W., Effect of prophylactic treatment on suicide risk in patients with major affective disorders. Data from a randomized prospective trial. Pharmacopsychiatry, 1996, 29 (3), 103-107.
156. Muller-Oerlinghausen, B.; Muser-Causemann, B.; Volk, J., Suicides and parasuicides in a high-risk patient group on and off lithium long-term medication. J. Affect. Disord., 1992, 25 (4), 261-269.
157. Smith, W. L.; Marnett, L. J.; DeWitt, D. L., Prostaglandin and thromboxane biosynthesis. Pharmacol. Ther., 1991, 49 (3), 153-179.
158. Smith, W. L.; DeWitt, D. L., Biochemistry of prostaglandin endoperoxide H synthase-1 and synthase-2 and their differential susceptibility to nonsteroidal anti-inflammatory drugs. Semin. Nephrol., 1995, 15 (3), 179-194.
159. Hewett, S. J.; Uliasz, T. F.; Vidwans, A. S.; Hewett, J. A., Cyclooxygenase-2 contributes to N-methyl-D-Aspartate-mediated neuronal cell death in primary cortical cell culture. J. Pharmacol. Exp. Ther., 2000, 293 (2), 417-425. (Pubitemid 30244090)
160. Muller, N.; Strassnig, M.; Schwarz, M. J.; Ulmschneider, M.; Riedel, M., COX-2 inhibitors as adjunctive therapy in schizophrenia. Expert Opin. Investig. Drugs, 2004, 13 (8), 1033-1044. (Pubitemid 39117689)
161. Acarin, L.; Peluffo, H.; Gonzalez, B.; Castellano, B., Expression of inducible nitric oxide synthase and cyclooxygenase-2 after excitotoxic damage to the immature rat brain. J. Neurosci. Res. 2002, 68 (6), 745-754. (Pubitemid 34594991)
162. Choi, S. H.; Joe, E. H.; Kim, S. U.; Jin, B. K., Thrombin-induced microglial activation produces degeneration of nigral dopaminergic neurons in vivo. J. Neurosci., 2003, 23 (13), 5877-5886. (Pubitemid 36807867)
163. Muller, N.; Schwarz, M. J., COX-2 inhibition in schizophrenia and major depression. Curr. Pharm. Des., 2008, 14 (14), 1452-1465. (Pubitemid 351982552)
164. Muller, N.; Myint, A. M.; Schwarz, M. J., The impact of neuroimmune dysregulation on neuroprotection and neurotoxicity in psychiatric disorders-relation to drug treatment. Dialogues Clin. Neurosci., 2009, 11 (3), 319-332.
165. Muller, N.; Ulmschneider, M.; Scheppach, C.; Schwarz, M. J.; Ackenheil, M.; Moller, H. J.; Gruber, R.; Riedel, M., COX-2 inhibition as a treatment approach in schizophrenia: immunological considerations and clinical effects of celecoxib add-on therapy. Eur. Arch. Psychiatry Clin. Neurosci., 2004, 254 (1), 14-22. (Pubitemid 39310544)
166. Muller, N.; Krause, D.; Dehning, S.; Musil, R.; Schennach-Wolff, R.; Obermeier, M.; Moller, H. J.; Klauss, V.; Schwarz, M. J.; Riedel, M., Celecoxib treatment in an early stage of schizophrenia: results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment. Schizophr. Res., 2010, 121 (1-3), 118-124.
167. Domercq, M.; Matute, C., Neuroprotection by tetracyclines. Trends Pharmacol. Sci., 2004, 25 (12), 609-612. (Pubitemid 39458165)
168. Bilousova, T. V.; Dansie, L.; Ngo, M.; Aye, J.; Charles, J. R.; Ethell, D. W.; Ethell, I. M., Minocycline promotes dendritic spine maturation and improves behavioural performance in the fragile X mouse model. J. Med. Genet., 2009, 46 (2), 94-102.
169. Defaux, A.; Zurich, M. G.; Honegger, P.; Monnet-Tschudi, F., Minocycline promotes remyelination in aggregating rat brain cell cultures after interferongamma plus lipopolysaccharide-induced demyelination. Neuroscience, 2011, 187, 84-92.
170. Henry, C. J.; Huang, Y.; Wynne, A.; Hanke, M.; Himler, J.; Bailey, M. T.; Sheridan, J. F.; Godbout, J. P., Minocycline attenuates lipopolysaccharide (LPS)-induced neuroinflammation, sickness behavior, and anhedonia. J. Neuroinflammation., 2008, 5, 15.
171. Stirling, D. P.; Koochesfahani, K. M.; Steeves, J. D.; Tetzlaff, W., Minocycline as a neuroprotective agent. Neuroscientist. 2005, 11 (4), 308-322. (Pubitemid 41040860)
172. Kim, H. S.; Suh, Y. H., Minocycline and neurodegenerative diseases. Behav. Brain Res., 2009, 196 (2), 168-179.
173. Derecki, N. C.; Cardani, A. N.; Yang, C. H.; Quinnies, K. M.; Crihfield, A.; Lynch, K. R.; Kipnis, J., Regulation of learning and memory by meningeal immunity: a key role for IL-4. J. Exp. Med., 2010, 207 (5), 1067-1080.
174. Plane, J. M.; Shen, Y.; Pleasure, D. E.; Deng, W., Prospects for minocycline neuroprotection. Arch. Neurol., 2010, 67 (12), 1442-1448.
175. Baptiste, D. C.; Fehlings, M. G., Pharmacological approaches to repair the injured spinal cord. J. Neurotrauma, 2006, 23 (3-4), 318-334. (Pubitemid 43726313)
176. Fujita, Y.; Ishima, T.; Kunitachi, S.; Hagiwara, H.; Zhang, L.; Iyo, M.; Hashimoto, K., Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the antibiotic drug minocycline. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2008, 32 (2), 336-339. (Pubitemid 351178944)
177. Mizoguchi, H.; Takuma, K.; Fukakusa, A.; Ito, Y.; Nakatani, A.; Ibi, D.; Kim, H. C.; Yamada, K., Improvement by minocycline of methamphetamine-induced impairment of recognition memory in mice. Psychopharmacology (Berl), 2008, 196 (2), 233-241.
178. Zhang, L.; Shirayama, Y.; Iyo, M.; Hashimoto, K., Minocycline attenuates hyperlocomotion and prepulse inhibition deficits in mice after administration of the NMDA receptor antagonist dizocilpine. Neuropsychopharmacology, 2007, 32 (9), 2004-2010. (Pubitemid 47258509)
179. Ahuja, N.; Carroll, B. T., Possible anti-catatonic effects of minocycline in patients with schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2007, 31 (4), 968-969. (Pubitemid 46671479)
180. Chaves, C.; de Marque, C. R.; Wichert-Ana, L.; Maia-de-Oliveira, J. P.; Itikawa, E. N.; Crippa, J. A.; Zuardi, A. W.; Todd, K. G.; Baker, G. B.; Dursun, S. M.; Hallak, J. E., Functional neuroimaging of minocycline's effect in a patient with schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2010, 34 (3), 550-552.
181. Kelly, D. L.; Vyas, G.; Richardson, C. M.; Koola, M.; McMahon, R. P.; Buchanan, R. W.; Wehring, H. J., Adjunct minocycline to clozapine treated patients with persistent schizophrenia symptoms. Schizophr. Res., 2011, 133 (1-3), 257-258.
182. Levkovitz, Y.; Mendlovich, S.; Riwkes, S.; Braw, Y.; Levkovitch-Verbin, H.; Gal, G.; Fennig, S.; Treves, I.; Kron, S., A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia. J. Clin. Psychiatry, 2010, 71 (2), 138-149.
183. Miyaoka, T.; Yasukawa, R.; Yasuda, H.; Hayashida, M.; Inagaki, T.; Horiguchi, J., Possible antipsychotic effects of minocycline in patients with schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2007, 31 (1), 304-307. (Pubitemid 44959270)
184. Miyaoka, T., Clinical potential of minocycline for schizophrenia. CNS Neurol. Disord. Drug Targets, 2008, 7 (4), 376-381.
185. Chaudhry, I. B.; Hallak, J.; Husain, N.; Minhas, F. A.; Stirling, J.; Richardson, P.; Dursun, S.; Dunn, G.; Deakin, B., Minocycline benefits negative symptoms in early schizophrenia; a randomised double-blind placebo-controlled clinical trial in patients on standard treatment. J. Psychopharmacol., 2012.
186. Kato, T. A.; Watabe, M.; Tsuboi, S.; Ishikawa, K.; Hashiya, K.; Monji, A.; Utsumi, H.; Kanba, S., Minocycline Modulates Human Social Decision-Making: Possible Impact of Microglia on Personality-Oriented Social Behaviors. PLoS One, 2012, 7 (7), e40461.
187. Watabe, M.; Kato, T. A.; Monji, A.; Horikawa, H.; Kanba, S., Does minocycline, an antibiotic with inhibitory effects on microglial activation, sharpen a sense of trust in social interaction? Psychopharmacology (Berl), 2012, 220 (3), 551-557.
188. Minichiello, L., TrkB signalling pathways in LTP and learning. Nat. Rev. Neurosci., 2009, 10 (12), 850-860.
189. Poo, M. M., Neurotrophins as synaptic modulators. Nat. Rev. Neurosci., 2001, 2 (1), 24-32.
190. Sen, S.; Duman, R.; Sanacora, G., Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-Analyses and implications. Biol. Psychiatry, 2008, 64 (6), 527-532.
191. Angelucci, F.; Brene, S.; Mathe, A. A., BDNF in schizophrenia, depression and corresponding animal models. Mol. Psychiatry, 2005, 10 (4), 345-352.
192. Berton, O.; Nestler, E. J., New approaches to antidepressant drug discovery: beyond monoamines. Nat. Rev. Neurosci., 2006, 7 (2), 137-151. (Pubitemid 43151600)
193. Duman, R. S.; Monteggia, L. M., A neurotrophic model for stress-related mood disorders. Biol. Psychiatry, 2006, 59 (12), 1116-1127.
194. Li, Y.; Luikart, B. W.; Birnbaum, S.; Chen, J.; Kwon, C. H.; Kernie, S. G.; Bassel-Duby, R.; Parada, L. F., TrkB regulates hippocampal neurogenesis and governs sensitivity to antidepressive treatment. Neuron, 2008, 59 (3), 399-412.
195. Hashimoto, K., Brain-derived neurotrophic factor as a biomarker for mood disorders: an historical overview and future directions. Psychiatry Clin. Neurosci., 2010, 64 (4), 341-357.
196. Elkabes, S.; DiCicco-Bloom, E. M.; Black, I. B., Brain microglia/macrophages express neurotrophins that selectively regulate microglial proliferation and function. J. Neurosci., 1996, 16 (8), 2508-2521. (Pubitemid 26122673)
197. Nakajima, K.; Honda, S.; Tohyama, Y.; Imai, Y.; Kohsaka, S.; Kurihara, T., Neurotrophin secretion from cultured microglia. J. Neurosci. Res., 2001, 65 (4), 322-331. (Pubitemid 32727034)
198. Zhang, J.; Geula, C.; Lu, C.; Koziel, H.; Hatcher, L. M.; Roisen, F. J., Neurotrophins regulate proliferation and survival of two microglial cell lines in vitro. Exp. Neurol., 2003, 183 (2), 469-481. (Pubitemid 37205088)
199. Batchelor, P. E.; Liberatore, G. T.; Wong, J. Y.; Porritt, M. J.; Frerichs, F.; Donnan, G. A.; Howells, D. W., Activated macrophages and microglia induce dopaminergic sprouting in the injured striatum and express brainderived neurotrophic factor and glial cell line-derived neurotrophic factor. J. Neurosci., 1999, 19 (5), 1708-1716. (Pubitemid 29094189)
200. Coull, J. A.; Beggs, S.; Boudreau, D.; Boivin, D.; Tsuda, M.; Inoue, K.; Gravel, C.; Salter, M. W.; De Koninck, Y., BDNF from microglia causes the shift in neuronal anion gradient underlying neuropathic pain. Nature, 2005, 438 (7070), 1017-1021. (Pubitemid 43093974)
201. Rose, C. R.; Blum, R.; Pichler, B.; Lepier, A.; Kafitz, K. W.; Konnerth, A., Truncated TrkB-T1 mediates neurotrophin-evoked calcium signalling in glia cells. Nature, 2003, 426 (6962), 74-78. (Pubitemid 37432543)
202. Mizoguchi, Y.; Monji, A.; Kato, T.; Seki, Y.; Gotoh, L.; Horikawa, H.; Suzuki, S. O.; Iwaki, T.; Yonaha, M.; Hashioka, S.; Kanba, S., Brain-derived neurotrophic factor induces sustained elevation of intracellular Ca2+ in rodent microglia. J. Immunol., 2009, 183 (12), 7778-7786.
203. Mizoguchi, Y.; Monji, A.; Kato, T. A.; Horikawa, H.; Seki, Y.; Kasai, M.; Kanba, S.; Yamada, S., Possible role of BDNF-induced microglial intracellular Ca(2+) elevation in the pathophysiology of neuropsychiatric disorders. Mini Rev. Med. Chem., 2011, 11 (7), 575-581.
204. Heneka, M. T.; O'Banion, M. K.; Terwel, D.; Kummer, M. P., Neuroinflammatory processes in Alzheimer's disease. J. Neural. Transm., 2010, 117 (8), 919-947.
205. Goddard, A. W.; Ball, S. G.; Martinez, J.; Robinson, M. J.; Yang, C. R.; Russell, J. M.; Shekhar, A., Current perspectives of the roles of the central norepinephrine system in anxiety and depression. Depress. Anxiety, 2010, 27 (4), 339-350.
206. Berridge, C. W.; Schmeichel, B. E.; Espana, R. A., Noradrenergic modulation of wakefulness/arousal. Sleep Med. Rev., 2012, 16 (2), 187-197.
207. Wohleb, E. S.; Hanke, M. L.; Corona, A. W.; Powell, N. D.; Stiner, L. M.; Bailey, M. T.; Nelson, R. J.; Godbout, J. P.; Sheridan, J. F., beta-Adrenergic receptor antagonism prevents anxiety-like behavior and microglial reactivity induced by repeated social defeat. J. Neurosci., 2011, 31 (17), 6277-6288.
208. Shad, M. U.; Suris, A. M.; North, C. S., Novel combination strategy to optimize treatment for PTSD. Hum. Psychopharmacol., 2011.
209. Cipriani, A.; Furukawa, T. A.; Salanti, G.; Geddes, J. R.; Higgins, J. P.; Churchill, R.; Watanabe, N.; Nakagawa, A.; Omori, I. M.; McGuire, H.; Tansella, M.; Barbui, C., Comparative efficacy and acceptability of 12 newgeneration antidepressants: a multiple-treatments meta-Analysis. Lancet, 2009, 373 (9665), 746-758.
210. Fonnum, F., Glutamate: a neurotransmitter in mammalian brain. J. Neurochem., 1984, 42 (1), 1-11. (Pubitemid 14216942)
211. Shimizu, E.; Tang, Y. P.; Rampon, C.; Tsien, J. Z., NMDA receptordependent synaptic reinforcement as a crucial process for memory consolidation. Science, 2000, 290 (5494), 1170-1174.
212. Bliss, T. V.; Collingridge, G. L., A synaptic model of memory: long-term potentiation in the hippocampus. Nature, 1993, 361 (6407), 31-39. (Pubitemid 23020772)
213. Lipton, S. A.; Rosenberg, P. A., Excitatory amino acids as a final common pathway for neurologic disorders. N. Engl. J. Med., 1994, 330 (9), 613-622.
214. Olanow, C. W.; Tatton, W. G., Etiology and pathogenesis of Parkinson's disease. Annu. Rev. Neurosci., 1999, 22, 123-144. (Pubitemid 29144883)
215. Farber, N. B.; Newcomer, J. W.; Olney, J. W., The glutamate synapse in neuropsychiatric disorders. Focus on schizophrenia and Alzheimer's disease. Prog. Brain Res., 1998, 116, 421-437. (Pubitemid 28526951)
216. Reisberg, B.; Doody, R.; Stoffler, A.; Schmitt, F.; Ferris, S.; Mobius, H. J.; Memantine Study, G., Memantine in moderate-to-severe Alzheimer's disease. N. Engl. J. Med., 2003, 348 (14), 1333-1341. (Pubitemid 36384100)
217. Manji, H. K.; Drevets, W. C.; Charney, D. S., The cellular neurobiology of depression. Nat. Med., 2001, 7 (5), 541-547. (Pubitemid 32448319)
218. Olney, J. W.; Farber, N. B., Glutamate receptor dysfunction and schizophrenia. Arch. Gen. Psychiatry, 1995, 52 (12), 998-1007.
219. Chang, Y.; Lee, J. J.; Hsieh, C. Y.; Hsiao, G.; Chou, D. S.; Sheu, J. R., Inhibitory effects of ketamine on lipopolysaccharide-induced microglial activation. Mediators Inflamm., 2009, 2009, 705379.
220. Mei, X. P.; Zhou, Y.; Wang, W.; Tang, J.; Zhang, H.; Xu, L. X.; Li, Y. Q., Ketamine depresses toll-like receptor 3 signaling in spinal microglia in a rat model of neuropathic pain. Neurosignals, 2011, 19 (1), 44-53.
221. Zarate, C. A., Jr.; Singh, J. B.; Carlson, P. J.; Brutsche, N. E.; Ameli, R.; Luckenbaugh, D. A.; Charney, D. S.; Manji, H. K., A randomized trial of an N-methyl-D-Aspartate antagonist in treatment-resistant major depression. Arch. Gen. Psychiatry, 2006, 63 (8), 856-864. (Pubitemid 44188478)
222. Salvadore, G.; Cornwell, B. R.; Colon-Rosario, V.; Coppola, R.; Grillon, C.; Zarate, C. A., Jr.; Manji, H. K., Increased anterior cingulate cortical activity in response to fearful faces: a neurophysiological biomarker that predicts rapid antidepressant response to ketamine. Biol. Psychiatry, 2009, 65 (4), 289-295.
223. Steiner, J.; Walter, M.; Gos, T.; Guillemin, G. J.; Bernstein, H. G.; Sarnyai, Z.; Mawrin, C.; Brisch, R.; Bielau, H.; Meyer zu Schwabedissen, L.; Bogerts, B.; Myint, A. M., Severe depression is associated with increased microglial quinolinic acid in subregions of the anterior cingulate gyrus: evidence for an immune-modulated glutamatergic neurotransmission? J. Neuroinflammation, 2011, 8, 94.
224. Wu, H. M.; Tzeng, N. S.; Qian, L.; Wei, S. J.; Hu, X.; Chen, S. H.; Rawls, S. M.; Flood, P.; Hong, J. S.; Lu, R. B., Novel neuroprotective mechanisms of memantine: increase in neurotrophic factor release from astroglia and antiinflammation by preventing microglial activation. Neuropsychopharmacology, 2009, 34 (10), 2344-2357.
225. Rosi, S.; Vazdarjanova, A.; Ramirez-Amaya, V.; Worley, P. F.; Barnes, C. A.; Wenk, G. L., Memantine protects against LPS-induced neuroinflammation, restores behaviorally-induced gene expression and spatial learning in the rat. Neuroscience, 2006, 142 (4), 1303-1315. (Pubitemid 44636069)
226. Shiba, T.; Yamato, M.; Kudo, W.; Watanabe, T.; Utsumi, H.; Yamada, K., In vivo imaging of mitochondrial function in methamphetamine-treated rats. Neuroimage, 2011, 57 (3), 866-872.
227. Matsumoto, K.; Hyodo, F.; Anzai, K.; Utsumi, H.; Mitchell, J. B.; Krishna, M. C., Brain redox imaging. Methods Mol. Biol., 2011, 711, 397-419.
228. Borgwardt, S.; Fusar-Poli, P., Third-generation neuroimaging in early schizophrenia: translating research evidence into clinical utility. Br. J. Psychiatry, 2012, 200 (4), 270-272.